ARK Genomic Revolution ETF holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
ARK Genomic Revolution ETF ARKG
Morningstar’s Analysis ARKG
Will ARKG outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 58.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
10x Genomics Inc Ordinary Shares - Class A | 9.26 | 197M | Healthcare |
Twist Bioscience Corp | 8.65 | 184M | Healthcare |
Tempus AI Inc Class A common stock | 8.18 | 174M | Healthcare |
CRISPR Therapeutics AG | 5.35 | 114M | Healthcare |
Absci Corp | 5.05 | 108M | Healthcare |
Illumina Inc | 4.83 | 103M | Healthcare |
Natera Inc | 4.65 | 99M | Healthcare |
Guardant Health Inc | 4.58 | 98M | Healthcare |
CareDx Inc | 4.08 | 87M | Healthcare |
Personalis Inc | 3.84 | 82M | Healthcare |